1. Introduction {#sec1}
===============

The prevalence of type 2 diabetes mellitus (T2DM) complicated by tuberculosis (TB) (T2DMTB) is rapidly increasing, resulting in detrimental effects on the economy and human health.

Clinical symptoms reveal that environmental factors play important roles in T2DM and TB. Because T2DMTB may be attributed to multiple causes, clinical experience indicates the traditional perspective that the two diseases are related in terms of nutrition. TB is associated with malnutrition, while T2DM is associated with excess nutrients. Thus, environmental factors, among which nutrition is one of the most important, alone, cannot explain the pathogenesis of two seemingly conflicting diseases occurring simultaneously in the same individual. In this case, genetic factors may be responsible for the development of T2DMTB \[[@B1]--[@B3]\], but we are not the first who are aware of host genetic factors that are important to determine the risk of type 2 diabetes mellitus complicated by tuberculosis. García-Elorriaga et al. \[[@B4]\] analyzed the association of inflammatory cytokine polymorphisms and T2DMTB in Mexico.

Toll-like receptor 4 (TLR~4~), a pattern recognition receptor, can recognize pathogen-associated molecular patterns (PAMPs) \[[@B5]\] and exacerbate and release inflammatory cytokines, such as TNF-*α*, IL-1*β*, IL-6, and IFN-*γ* \[[@B6]\].*Mycobacterium tuberculosis*presents liposaccharides (LPS), a type of PAMP. When TLR~4~ recognizes the LPS of*M. tuberculosis*, inflammatory cytokines are induced and released by the pathway of TLR~4~ \[[@B7]--[@B9]\]. This pathway is an important element in the innate immune system of the human body. TLR~4~, as an important mediator of inflammation, can recognize a variety of pathogens, including Gram-negative and Gram-positive bacteria \[[@B10]\]. Previous studies have shown that human TLR~4~ is a potentially important gene that may affect the onset of T2DM \[[@B11]--[@B13]\]. The receptor may be related to susceptibility to some infections that can induce diseases such as TBs \[[@B14]--[@B18]\]. To date, no study has yet reported the association between TLR~4~ gene polymorphisms and the risk of T2DMTB in the Chinese population.

We believe that TLR~4~ gene polymorphisms are a good starting point for studying T2DMTB. To be able to establish preventive measures for high-risk people as far as possible, in this study, we investigate the relationship between TLR~4~ gene polymorphisms and T2DMTB risk in Northeast China.

2. Material and Methods {#sec2}
=======================

2.1. Study Subject and Sample Collection {#sec2.1}
----------------------------------------

We recruited 238 cases with T2DMTB as the case group and 310 cases with T2DM as the control group. T2DMTB patient information was obtained from the Fourth Medical Ward, Heilongjiang Province Tuberculosis Control Center, from September 2013 to June 2015. T2DM patient information was obtained from the Second Department of Outpatient Services, Heilongjiang Province Tuberculosis Control Center, from September 2013 to November 2014.

Subjects with a history of blood-transmitted diseases, such as AIDS, hepatitis B, hepatitis C, or other endocrine diseases, were excluded from this study. Blood samples were taken from the patients, and DNA was obtained and stored in 193 K. Both doctors and study subjects provided consent to participate in this work, and the Ethics Committee of Harbin Medical University approved of this research.

2.2. Immunohistochemical Method {#sec2.2}
-------------------------------

To determine whether serum TLR~4~ levels were consistent with the gene expression level, 40 serum samples were collected from the T2DMTB group and T2DM group, respectively, according to the principle of random. Serum TLR~4~ contents were detected by using an immunohistochemical method following the manufacturer\'s instructions (Beijing Cheng Lin Biological Technology Co., Ltd.).

2.3. Tag SNP Selection and Genotyping {#sec2.3}
-------------------------------------

Tag SNPs of TLR~4~ gene were evaluated and selected by using the HapMap database (<https://hapmap.ncbi.nlm.nih.gov/>) with the following criterion: a minor allele frequency (MAF) \> 0.05 in the Chinese Han population in the National Center of Biotechnology Information Database; linkage disequilibrium (LD) blocks were established by using Chinese LD maps and *r* ^2^ \> 0.8. Six tag SNPs representing the genetic information of TLR~4~ were selected for genotyping: rs1927914 located in the promoter region; rs11536879, rs1927911, and rs1927907 located in the intron region; and rs11536889 and rs7873784 located in the 3′-UTR region.

According to the manufacturer\'s instructions, genomic DNA was extracted from peripheral blood using a Tiangen DNA Blood Mini kit (Tiangen Biotech Co., Ltd., Beijing, China). All SNPs were genotyped using fluorogenic 5′-nuclease assay (TaqMan SNP Genotyping Assay, Applied Biosystems, Foster City, CA, USA). For quality control, 20% of all of the samples were performed in delicate form randomly for each SNP. The concordance rate of these repeated samples was 100%.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Numerical data are expressed as mean ± SD. Student\'s*t-*test was performed to analyze differences between the T2DMTB and T2DM groups.

Fisher\'s exact test was used to evaluate the Hardy-Weinberg equilibrium (HWE) in the subjects. The chi-square test or Fisher\'s exact test was used to identify statistical differences in the distributions of clinic pathological characteristics. Univariate and multivariate unconditional logistic regression were used to estimate crude and adjusted odds ratios (ORs) and 95% confidence intervals (CIs), all of which measured the associations between the risk factors of T2DMTB compared with T2DM. Two-sided *p* \< 0.05 was considered as statistically significant. Statistical analysis was carried out by using SAS software (version 9.1.3, SAS Institute, Cary, NC).

3. Results {#sec3}
==========

3.1. Demographic Characteristics {#sec3.1}
--------------------------------

A total of 548 people participated in this study, including 238 cases of T2MDTB and 310 cases of T2MD. Among the patients, 338 were male and 210 were female. The mean ages of T2DMTB and T2DM patients were 51.97 ± 11.87 years and 58.73 ± 11.46 years, respectively. The demographic characteristics of the patients are shown in [Table 1](#tab1){ref-type="table"}.

3.2. Serum TLR~4~ Levels of Patients with T2DMTB and Patients with T2DM {#sec3.2}
-----------------------------------------------------------------------

The serum TLR~4~ levels of subjects with T2DMTB were significantly lower than those of subjects suffering from T2DM (*p* \< 0.0001). No differences in the basic characteristics of the participants, including gender (*p* = 0.260) and age (*p* = 0.631), were observed ([Table 2](#tab2){ref-type="table"}).

3.3. Distributions of SNP Genotypes between Patients with T2DMTB and Patients with T2DM {#sec3.3}
---------------------------------------------------------------------------------------

Genotype distributions did not show statistically significant deviations from HWE for all SNPs in this study ([Table 3](#tab3){ref-type="table"}).

3.4. Distribution of Allelic Genes of SNPs between Patients with T2DMTB and Patients with T2DM {#sec3.4}
----------------------------------------------------------------------------------------------

The distributions of allelic genes of six SNPs of the TLR~4~ gene were not statistically significant between patients with T2DMTB and patients with T2DM. Details of these distributions are summarized in [Table 4](#tab4){ref-type="table"}.

3.5. SNPs and T2DMTB Risk {#sec3.5}
-------------------------

The SNPs of TLR~4~ were not significantly associated with T2DMTB risk. No significant differences in genotype distributions between patients with T2DMTB and patients with T2DM were observed using the recessive and dominant genetic models ([Table 5](#tab5){ref-type="table"}). However, potential trends may provide useful information for future studies. In rs7873784, compared with the GG genotype, the GC genotype presented lower risks of T2DMTB (OR~adjusted~ = 0.69, 95% CI: 0.42--1.14, *p* = 0.15). In rs11536879, AG genotype carriers showed decreased risk of T2DMTB compared with the GG genotype (OR~adjusted~ = 0.68, 95% CI: 0.43--1.08, *p* = 0.10).

4. Discussion {#sec4}
=============

A previous study showed that patients with T2DM demonstrated four to eight times increased risk of tuberculosis compared to patients without T2DM. For instance, TB in T2DM patients was 5 times more prevalent than in non-T2DM patients in some regions in the USA, 5.4 times more prevalent than in non-T2DM patients in Australia, and 6.8 times more prevalent than in non-T2DM patients in Mexico \[[@B4]\].

In the clinic, we discovered that T2DMTB patients present uneven changes in inflammatory cytokines such as TNF-*α* and IFN-*γ*. Clinical examination of simple TB yielded a positive IFN-*γ* test, but the results of nearly all patients with T2DMTB were negative. TLR~4~ is an important element of the endogenic immune system and it can induce and release inflammatory cytokines \[[@B5]\]. TLR~4~ is an important element of the innate immune system of the human body. Thus, we hypothesize that serum TLR~4~ exhibits obvious changes in T2DMTB patients. We examined TLR~4~ serum levels in patients with T2DMTB and patients T2DM to determine whether TLR~4~ is involved in the susceptibility of T2DM patients suffering from TB in Northeast China. While no study has yet proven that TLR~4~ polymorphisms are related to T2DMTB or T2DM, other studies \[[@B19]--[@B22]\] indicate that TLR~4~ polymorphisms present statistically significant differences between healthy people and patients with TB.

Our study results are different from those of Wu et al. \[[@B23]\], especially in terms of the frequencies of the GG genotype of SNP rs7873784 in TLR~4~ (OR = 2.136; 95% CI: 1.312--3.478) and the CC genotype of rs3764879 in TLR~8~ (OR = 1.982; 95% CI: 1.292--3.042). It was also significantly higher in the TB group than in the healthy group. Arji et al. \[[@B24]\] found TLR~4~ interactions influencing protection against TB in Moroccan patients. The present work and that of Jahantigh et al. \[[@B25]\] both demonstrated no significant relation between TLR~4~ and TLR~9~ polymorphisms and TB. Sánchez et al. \[[@B26]\] reported that they did not find any association between TLR~4~ polymorphic variants. These findings suggest that the gene polymorphisms were not involved in any risk factor for pulmonary TB in the Colombian population \[[@B26]\]. The same result was obtained by Xue et al. \[[@B27]\], who discovered that these polymorphisms were rare in the Southeastern Chinese population and not linked to susceptibility to TB. Newport et al. \[[@B28]\] also have studied that, but result was that no association between TLR~4~ Asp299Gly and TB was observed.

The result of our study showed that it was negative. The reasons behind this result are first the size of the sample which was not enough. The second one is the geographic regions and genetic factors, because we were focused on the people of Northeast China in our work just only.

The purpose of this study is to determine why patients with T2DM easily develop pulmonary TB. Thus, we did not detect TLR~4~ gene polymorphisms in healthy cases and we did not compare changes in TLR~4~ gene polymorphisms among healthy cases, patients with T2DM, and patients with T2DMTB. Changes in TLR~4~ gene polymorphisms may have already occurred in most patients with T2DM. In this case, a false negative result may appear if a comparison was carried out between T2DM patients and patients suffering from T2DMTB only. Such a phenomenon would also confirm some reports that T2DM is characterized by chronic inflammation.

Some studies have recently mentioned that the risk genotypes of rs1927914 are significantly linked with diabetic foot ulcers \[[@B29]\]; the research team of Singh \[[@B30]\] also found that the combined genotype risks of TLR~4~ SNPs rs10759931 (odds ratio \[OR\] 1.50, *p* = 0.05) and rs1927914 (OR 1.48, *p* = 0.05) were significantly linked to retinopathy in T2DM. These works support the idea that T2DM is a chronic inflammatory disease. It is possible that T2DM patients already had TLR~4~ gene polymorphism. Therefore, we considered these points as the third reason.

Two groups of patients were included in our study. For each group, we concerned about the changing of TLR~4~ gene polymorphism and no changing of TLR~4~ levels in the blood. The reason of that was hidden behind the changing in the TLR~4~ gene, because serum TLR~4~ is a sensitivity index but not a specific index. Chronic inflammation could directly lead to changes in TLR~4~ in the blood or other gene polymorphisms that could lead to TLR~4~ changes in the blood. Our study was limited by considering just TLR~4~ gene polymorphisms. Other inflammatory gene polymorphisms that promote development of T2DMTB may exist.

The results of this study reveal that TLR~4~ changes at the molecular level are insignificant because the changes at the gene level may be not significant. Our results also demonstrated no significant link between the six SNPs of TLR~4~ studied in this work and the susceptibility of patients with T2DMTB in Northeast China. Future studies may be performed to determine the causes of T2DMTB from the perspective of genetics. We aim to determine the marker gene polymorphism in T2DM and show how it can be complicated by TB.
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###### 

Demographic characteristics of the subjects.

  Variable                T2DMTB   T2DM   Total   *p* value
  ----------------------- -------- ------ ------- -----------
  Age                                              
   ⩽50                    104      68     172     \<0.0001
   50--60                 73       108    181     
   60--70                 45       80     125     
    *⩾*70                 16       54     70      
  Gender                                           
   Male                   167      171    338     0.0003
   Female                 71       139    210     
  BMI                                              
   ⩽18.5                  35       8      43      \<0.0001
   18.5--24               112      64     176     
    *⩾*24                 91       238    329     
  Smoking                                          
   Yes                    132      86     218     \<0.0001
   No                     106      224    330     
  Drinking                                         
   Yes                    108      94     202     0.0003
   No                     130      216    346     
  Glucose                                          
   \<5.0                  12       13     25      0.0857
   5.0--7.2               48       88     136     
   \>7.2                  178      209    387     
  Insulin use                                      
   Use                    112      196    308     \<0.0001
   No use                 126      112    238     
   Unclear                0        2      2       
  Hypoglycemic drug use                            
   Use                    45       224    269     \<0.0001
   No use                 193      80     273     
   Unclear                0        6      6       

###### 

Serum TLR~4~ levels of patients with T2DMTB and T2DM.

  Variable               T2DMTB         T2DM           *p* value
  ---------------------- -------------- -------------- -----------
  Gender (male/female)   40 (20/20)     40 (25/15)     0.260
  Age (years)            51.17 ± 6.70   51.85 ± 6.20   0.631
  TLR~4~ (ng/mL)         15.27 ± 2.52   19.40 ± 1.80   \<0.0001

###### 

Distributions of SNP genotypes and Hardy-Weinberg equilibrium.

  ----------------------------------------------------------------------------
               T2DMTB\       T2DM\         *p* value   Hardy-Weinberg   
               No. (%)       No. (%)                                    
  ------------ ------------- ------------- ----------- ---------------- ------
  rs7873784                                                              

   GG          243 (86.17)   236 (83.69)   0.19        0.56             0.46

   GC          35 (12.41)    45 (15.96)                                 

   CC          4 (1.42)      1 (0.35)                                   

  rs11536889                                                             

   GG          176 (61.97)   181 (64.41)   0.83        0.81             0.37

   GC          93 (32.75)    86 (30.61)                                 

   CC          15 (5.28)     14 (4.98)                                  

  rs1927914                                                              

   TT          90 (31.91)    102 (36.17)   0.50        0.53             0.47

   CT          145 (51.42)   140 (49.65)                                

   CC          47 (16.67)    40 (14.18)                                 

  rs1927911                                                              

   TT          97 (34.28)    96 (34.16)    0.48        2.92             0.09

   CT          139 (49.12)   148 (52.67)                                

   CC          47 (16.61)    37 (13.17)                                 

  rs1927907                                                              

   GG          145 (51.24)   147 (52.31)   0.96        2.12             0.15

   AG          123 (43.46)   119 (42.35)                                

   AA          15 (5.30)     15 (5.34)                                  

  rs11536879                                                             

   AA          230 (82.44)   215 (77.62)   0.20        1.04             0.31

   AG          41 (14.70)    56 (20.22)                                 

   GG          8 (2.87)      6 (2.17)                                   
  ----------------------------------------------------------------------------

###### 

Distributions of allelic genes of SNPs between patients with T2DMTB and patients with T2DM.

  SNP          Allelic genes   T2DMTB   T2DM    *p* value           
  ------------ --------------- -------- ------- ----------- ------- ------
  rs7873784    G allele        521      92.36   517         91.67   0.74
  C allele     43              7.64     47      8.33                
                                                                    
  rs11536889   G allele        445      78.35   448         79.72   0.61
  C allele     123             21.65    114     20.28               
                                                                    
  rs1927914    T allele        325      57.62   344         60.99   0.43
  C allele     229             42.38    220     39.01               
                                                                    
  rs1927911    T allele        333      58.83   340         60.50   0.59
  C allele     233             41.17    222     39.50               
                                                                    
  rs1927907    G allele        413      72.97   413         73.49   0.89
  A allele     153             27.03    149     26.51               
                                                                    
  rs11536879   A allele        501      89.78   486         87.73   0.30
  G allele     57              10.22    68      12.27               

###### 

Associations between the SNPs of TLR~4~ and DMTB risk.

  Genotype        Crude OR (95% CI)    *p* value   Adjusted OR (95% CI)^*∗*^   *p* value
  --------------- -------------------- ----------- --------------------------- -----------
  rs7873784                                                                     
   GG             1.00                             1.00                         
   GC             0.76 (0.47--1.22)    0.25        0.69 (0.42--1.14)           0.15
   CC             3.89 (0.43--35.01)   0.23        3.16 (0.33--30.74)          0.32
   CC/(GG + GC)   4.04 (0.45--36.41)   0.21        3.34 (0.34--32.38)          0.30
   (GC + CC)/GG   0.82 (0.52--1.31)    0.41        0.75 (0.46--1.22)           0.25
  rs11536889                                                                    
   GG             1.00                             1.00                         
   GC             1.12 (0.78--1.60)    0.54        1.04 (0.71--1.51)           0.85
   CC             1.11 (0.52--2.36)    0.79        1.08 (0.49--2.39)           0.85
   CC/(GG + GC)   1.07 (0.51--2.26)    0.86        1.07 (0.49--2.34)           0.87
   (GC + CC)/GG   1.12 (0.79--1.57)    0.53        1.04 (0.73--1.49)           0.82
  rs1927914                                                                     
   TT             1.00                             1.00                         
   CT             1.17 (0.81--1.69)    0.39        1.25 (0.85--1.84)           0.25
   CC             1.33 (0.80--2.21)    0.27        1.35 (0.80--2.29)           0.27
   CC/(TT + CT)   1.21 (0.77--1.91)    0.42        1.18 (0.73--1.91)           0.49
   (CT + CC)/TT   1.21 (0.85--1.71)    0.29        1.28 (0.89--1.84)           0.19
  rs1927911                                                                     
   TT             1.00                             1.00                         
   CT             0.93 (0.65--1.34)    0.70        0.93 (0.63--1.36)           0.71
   CC             1.26 (0.75--2.10)    0.38        1.22 (0.72--2.09)           0.46
   CC/(TT + CT)   1.31 (0.82--2.09)    0.25        1.28 (0.79--2.08)           0.36
   (CT + CC)/TT   1.00 (0.70--1.41)    0.98        0.99 (0.69--1.43)           0.96
  rs1927907                                                                     
   GG             1.00                             1.00                         
   AG             1.05 (0.75--1.47)    0.79        1.03 (0.72--1.48)           0.86
   AA             1.01 (0.48--2.15)    0.97        0.95 (0.44--2.05)           0.89
   AA/(GG + AG)   0.99 (0.48--2.07)    0.98        0.93 (0.44--1.99)           0.85
   (AG + AA)/GG   1.04 (0.75--1.45)    0.80        1.02 (0.72--1.44)           0.90
  rs11536879                                                                    
   AA             1.00                             1.00                         
   AG             0.68 (0.44--1.07)    0.09        0.68 (0.43--1.08)           0.10
   GG             1.25 (0.43--3.65)    0.69        1.35 (0.45--4.04)           0.59
   GG/(AA + AG)   1.33 (0.46--3.89)    0.60        1.44 (0.48--4.31)           0.51
   (AG + GG)/AA   0.74 (0.49--1.12)    0.16        0.75 (0.48--1.15)           0.19

*Note*. ^*∗*^Age, gender, BMI, smoking, drinking, insulin use, and hypoglycemic drug use were adjusted.
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